Latest News

Latest News

Clinical Trials Roundup | 26 June 2026

Clinical Trials Roundup | 26 June 2026

This week's clinical trial results for 26 June 2026 deliver a landmark psychiatric result, a major oncology setback, and a decisive blow to one of the most watched platforms in regenerative medicine. Definium Therapeutics' DT120 becomes the first lysergide therapy to...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

UK Winter Flu 2025: Current Trends and Vaccine Advice

UK Winter Flu 2025: Current Trends and Vaccine Advice

As the UK enters the heart of the 2025 to 2026 winter respiratory season, influenza flu is emerging as a major public health challenge, with cases rising earlier and more sharply than usual. Health services are already under strain, and experts are urging the public...

read more
Metabolic Myths That Hold you Back

Metabolic Myths That Hold you Back

In the age of endless diet tips and health hacks, metabolic health has become one of the most misunderstood topics. People try hard… they cut calories, walk more, sleep less, snack less… yet nothing changes. The problem isn’t effort. It’s misinformation. Metabolic...

read more
Are Mega-Deals Back for Real?

Are Mega-Deals Back for Real?

By early Q4 2025, global pharma M&A had already crossed $70B in announced value, driven heavily by a handful of mega-deals, more than 2024, and tracking toward the highest levels since the post-2015 boom. Unlike 2023–24, this wave isn’t driven by small tuck-ins....

read more
AI Drug Discovery Moves from Hype to Measurable Output

AI Drug Discovery Moves from Hype to Measurable Output

Artificial intelligence is increasingly being judged on clinical progress and tangible outcomes, not just models and algorithms. Once a speculative concept, AI-driven drug discovery is now generating real-world data, advancing molecules into human studies, reshaping...

read more
The Science Behind Sleep, Exercise and Hydration Targets

The Science Behind Sleep, Exercise and Hydration Targets

For decades, public health messaging has revolved around simple numerical targets. Get eight hours of sleep. Exercise for 150 minutes a week. Drink eight glasses of water a day. These guidelines are easy to remember and widely promoted, but they also raise an...

read more
Must-Track Biomarkers

Must-Track Biomarkers

The Numbers That Reveal Your Metabolic Health Today… and Your Risk Tomorrow Most people rely on weight or BMI to judge their health… yet neither tells you how your metabolism is actually working. True metabolic health comes from understanding what’s happening inside...

read more
Gene and RNA Therapies Gain Momentum in Obesity Treatment

Gene and RNA Therapies Gain Momentum in Obesity Treatment

The field of obesity treatment is expanding beyond GLP 1 receptor agonists as a growing wave of gene modulating and RNA based therapies emerges. These next generation programmes aim to address fat accumulation, particularly visceral fat and metabolic dysfunction,...

read more
How Neurons Help Cancer Spread

How Neurons Help Cancer Spread

One of the biggest surprises in modern cancer biology is that tumors are wired with nerves—and cancers with more nerve fibers tend to be more aggressive. A new study finally explains why. The Key Finding Neurons actively transfer their mitochondria — the cell’s energy...

read more
UK Winter Flu 2025: Current Trends and Vaccine Advice

UK Winter Flu 2025: Current Trends and Vaccine Advice

As the UK enters the heart of the 2025 to 2026 winter respiratory season, influenza flu is emerging as a major public health challenge, with cases rising earlier and more sharply than usual. Health services are already under strain, and experts are urging the public...

read more
Metabolic Myths That Hold you Back

Metabolic Myths That Hold you Back

In the age of endless diet tips and health hacks, metabolic health has become one of the most misunderstood topics. People try hard… they cut calories, walk more, sleep less, snack less… yet nothing changes. The problem isn’t effort. It’s misinformation. Metabolic...

read more
Are Mega-Deals Back for Real?

Are Mega-Deals Back for Real?

By early Q4 2025, global pharma M&A had already crossed $70B in announced value, driven heavily by a handful of mega-deals, more than 2024, and tracking toward the highest levels since the post-2015 boom. Unlike 2023–24, this wave isn’t driven by small tuck-ins....

read more
AI Drug Discovery Moves from Hype to Measurable Output

AI Drug Discovery Moves from Hype to Measurable Output

Artificial intelligence is increasingly being judged on clinical progress and tangible outcomes, not just models and algorithms. Once a speculative concept, AI-driven drug discovery is now generating real-world data, advancing molecules into human studies, reshaping...

read more
The Science Behind Sleep, Exercise and Hydration Targets

The Science Behind Sleep, Exercise and Hydration Targets

For decades, public health messaging has revolved around simple numerical targets. Get eight hours of sleep. Exercise for 150 minutes a week. Drink eight glasses of water a day. These guidelines are easy to remember and widely promoted, but they also raise an...

read more
Must-Track Biomarkers

Must-Track Biomarkers

The Numbers That Reveal Your Metabolic Health Today… and Your Risk Tomorrow Most people rely on weight or BMI to judge their health… yet neither tells you how your metabolism is actually working. True metabolic health comes from understanding what’s happening inside...

read more
Gene and RNA Therapies Gain Momentum in Obesity Treatment

Gene and RNA Therapies Gain Momentum in Obesity Treatment

The field of obesity treatment is expanding beyond GLP 1 receptor agonists as a growing wave of gene modulating and RNA based therapies emerges. These next generation programmes aim to address fat accumulation, particularly visceral fat and metabolic dysfunction,...

read more
How Neurons Help Cancer Spread

How Neurons Help Cancer Spread

One of the biggest surprises in modern cancer biology is that tumors are wired with nerves—and cancers with more nerve fibers tend to be more aggressive. A new study finally explains why. The Key Finding Neurons actively transfer their mitochondria — the cell’s energy...

read more

Featured Articles

FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 31 July 2026. Covering target action dates from August to December 2026. The closing stretch of the third quarter has become the busiest regulatory window of 2026. Between early August and the end of September, the US Food and Drug Administration faces...
Pipette dispensing into lab vials with glowing DNA helix and genetic sequence data for Life Science Daily News

Life Science Daily News: Eight Months of Growth and a Global Community Taking Shape

Life Science Daily News launched in November 2025 with a simple premise: that researchers, biotech founders, healthcare professionals, communications specialists and industry professionals should be able to publish their own work directly to a specialist audience,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Otsuka Wins Approval for Novel Rare Kidney Drug

Otsuka Wins Approval for Novel Rare Kidney Drug

Otsuka Gains Approval for First of Its Kind Treatment Against Rare Kidney Disease In a significant milestone for kidney disease care, Otsuka Pharmaceutical has received accelerated approval from the US Food and Drug Administration for a new therapy for Immunoglobulin...

read more
US and UK Agree Zero Tariffs Deal on Pharmaceuticals

US and UK Agree Zero Tariffs Deal on Pharmaceuticals

US and UK Agree Zero Tariffs Deal on Pharmaceuticals: What It Means for Patients, Innovation and Global Pharma Trade The United States and the United Kingdom have reached a landmark trade agreement that eliminates tariffs on UK-origin pharmaceuticals, active...

read more
A Milestone in Rare Disease Genomics

A Milestone in Rare Disease Genomics

Why popEVE Matters Interpreting missense variants has long been one of the most persistent challenges in clinical genetics. These single–amino-acid substitutions can subtly alter protein structure or function, yet their effects are often context-dependent and...

read more
Brain Cell Communication at the Molecular Level

Brain Cell Communication at the Molecular Level

Brain Cell Communication at the Molecular Level Neural communication isn’t abstract, it’s a sequence of tightly regulated biophysical events. Ion gradients shift, channels open and close with millisecond precision, calcium signals trigger chemical release, and...

read more
Welcome to Life Science Daily News

Welcome to Life Science Daily News

Your Gateway to Discovery, Innovation, and Global Scientific Voices In a world where breakthroughs happen every day and scientific understanding is accelerating faster than ever before, Life Science Daily News stands as a vibrant hub for curious minds, passionate...

read more

Further News

Biotech M&A 2026: Every $1B+ Deal so Far and What is Driving Them

The biotech M&A 2026 market has entered what many analysts are already calling a breakout year. In the first four months of 2026 alone, pharma and biotech companies have signed deals worth approximately $84 billion, and the pipeline of transactions shows no sign...

Muscular Dystrophy Has New Treatments. Patients Still Can’t Get Diagnosed

A generation of transformative therapies is arriving for Duchenne muscular dystrophy. Gene therapies have reached the clinic. Oral small molecules targeting the fundamental biology of the disease are entering clinical trials. Newborn screening programmes are being...

Beyond GLP-1: The Future of Obesity Care is Hybrid

The emergence of GLP-1 receptor agonists has fundamentally reshaped obesity treatment. For the first time, we are seeing consistent, clinically meaningful weight loss at scale, supported by robust clinical programs such as STEP and SURMOUNT (Wilding et al., 2021;...

Using AI to Translate Fragmented Evidence into Formulation Logic

Thesis Early-stage life science development is increasingly constrained not by lack of data, but by fragmented, multi-scale evidence that resists straightforward interpretation. AI systems can assist in structuring this complexity – through literature triage,...

First Alzheimer’s Biomarker Reversal Linked to Lyme Disease Treatment

Alzheimer’s disease (AD) represents a significant medical concern for all of us as we grow older, as the NIH has published that the average risk of dementia over 55 years old is now 42%. AD is presently affecting 6.9 million Americans aged 65 or older and is expected...

Invisible Architect: How Infrastructure Drives Life Sciences Growth

In the high-stakes world of drug discovery and biomanufacturing, the spotlight typically shines on breakthrough modalities, venture rounds, and FDA milestones. Yet, behind every clinical success is a physical environment that either accelerated the science or quietly...

CagriSema: The Next Big Obesity Drug? What the Phase 3 Data Shows

The global obesity drug market is in the midst of its most competitive period in a generation. Since the approval of semaglutide as Wegovy and tirzepatide as Zepbound, pharmaceutical companies and investors have been watching closely for the next therapy capable of...

Weekly News Roundup | 11 May 2026

Life science news 11 May 2026: M&A momentum, artificial intelligence diagnostics and a record week for deal-making define an active seven days for the global life science industry. The week of 4 to 10 May 2026 produced a dense cluster of major acquisitions, a...

Why “Hot” Therapeutic Areas Break Traditional Benchmarks

In fast-moving areas like radiopharmaceuticals and precision immunology, the biggest portfolio risk is often not uncertainty itself, but false certainty created by mismatched benchmarks. As life sciences enters a more disciplined cycle, one pattern shows up across...

Is Photodisinfection the New Alternative to Traditional Antibiotics?

Few ideas in modern medicine are as unsettling as the prospect of a “post-antibiotic era.” For decades, antibiotics have underpinned infection control, transforming once-lethal diseases into manageable conditions. Yet their effectiveness is steadily eroding....

Orforglipron Approved: Inside the Oral GLP-1 Race

The obesity treatment landscape shifted decisively on 1 April 2026, when the US Food and Drug Administration approved Foundayo (orforglipron), an oral once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. The decision marks the arrival of...

Clinical Trials Roundup | 8 May 2026

Cytokinetics’ aficamten meets dual primary endpoints in the pivotal Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy, Axsome Therapeutics secures FDA approval of AUVELITY as the first non-antipsychotic treatment for Alzheimer’s disease...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.